American College of Rheumatology Applauds Additional Drugs Included in Second Round of Medicare Drug Price Negotiations
January 25, 2025
January 25, 2025
ATLANTA, Georgia, Jan. 25 -- The American College of Rheumatology issued the following statement on Jan. 24, 2025:
* * *
The American College of Rheumatology (ACR) applauded the announcement of additional drugs subject to pricing negotiations with the Centers for Medicare & Medicaid Services (CMS). This second round includes nintedanib (Ofev) and apremilast (Otezla), which are used to treat common and rare rheumatologic conditions.
"Excessive drug . . .
* * *
The American College of Rheumatology (ACR) applauded the announcement of additional drugs subject to pricing negotiations with the Centers for Medicare & Medicaid Services (CMS). This second round includes nintedanib (Ofev) and apremilast (Otezla), which are used to treat common and rare rheumatologic conditions.
"Excessive drug . . .